Drugs / S103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06958939 | May 2025 → Apr 2026 overdue | generalized myasthenia gravis | Ting Chang, MD | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-10 | Hebei Senlang Biotechnology Inc., Ltd. | Results 国际顶级期刊《Blood Advances》发表森朗生物靶向BCMA纳米抗体CAR-T产品在治疗复发或难治性浆细胞骨髓瘤中的最新临床研究成果 senlangbio.com ↗
近日，国际血液学领域顶级期刊《Blood Advances》报道了森朗生物自主研发的靶向BCMA纳米抗体CAR-T细胞（S103）多线治疗后难治复发的浆细胞肿瘤的突破性临床研究成果。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-10 | Hebei Senlang Biotechnology Inc., Ltd. | 国际顶级期刊《Blood Advances》发表森朗生物靶向BCMA纳米抗体CAR-T产品在治疗复发或难治性浆细胞骨髓瘤中的最新临床研究成果 senlangbio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S103 | “A Single-center, Single-arm, Dose-exploration Study Evaluating the Safety and Efficacy of SENL103 Autologous T-cell Injection (S103) in the Treatment of Refractory Generalized...” NCT06958939 ↗ |
| Known as | SENL103 | “A Single-center, Single-arm, Dose-exploration Study Evaluating the Safety and Efficacy of SENL103 Autologous T-cell Injection (S103) in the Treatment of Refractory Generalized...” NCT06958939 ↗ |
| Modality | Cell therapy | “BCMA CAR-T（S103）” NCT06958939 ↗ |